<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04337463</url>
  </required_header>
  <id_info>
    <org_study_id>ATG-008-HX-001</org_study_id>
    <nct_id>NCT04337463</nct_id>
  </id_info>
  <brief_title>ATG-008 Combined With Toripalimab in Advanced Solid Tumors</brief_title>
  <official_title>An Open, Dose-escalation and Expansion Study With a Dual TORC1/2 Inhibitor of ATG-008 Combined With PD-1 Antibody of Toripalimab in Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sichuan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sichuan University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, single-arm study with dose-escalation and expansion phases to access&#xD;
      ATG-008 combined with Toripalimab in patients with advanced solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 23, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MTD</measure>
    <time_frame>Within 21 days after dosing</time_frame>
    <description>Maximum Tolerated Dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>RP2D</measure>
    <time_frame>Within 21 days after dosing</time_frame>
    <description>Recommended phase 2 dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ORR</measure>
    <time_frame>Through study completion (approximately 2 years)</time_frame>
    <description>Overall Response Rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>Day 1 - Day 15</time_frame>
    <description>Peak Plasma Concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC</measure>
    <time_frame>Day 1 - Day 15</time_frame>
    <description>Area under the plasma concentration versus time curve (AUC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DOR</measure>
    <time_frame>12 months</time_frame>
    <description>Duration from the first observation of at least PR to time of disease progression, or deaths due to disease progression, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DCR</measure>
    <time_frame>12 months</time_frame>
    <description>Disease Control Rate (DCR=CBR+Stable Disease[SD; for a minimum of 12 weeks])</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>12 months</time_frame>
    <description>Duration from start of study treatment to PD or death (regardless of cause), whichever comes first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>12 months</time_frame>
    <description>The estimates of Kaplan-Meier</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Advanced Solid Tumor</condition>
  <arm_group>
    <arm_group_label>ATG-008 and Toripalimab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Toripalimab will be combined with ATG-008.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATG-008</intervention_name>
    <description>Tablet</description>
    <arm_group_label>ATG-008 and Toripalimab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Toripalimab</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>ATG-008 and Toripalimab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Know and voluntarily sign informed consent.&#xD;
&#xD;
          2. Age 18-70 years old (including 18 and 70 years old), weight ≥45 Kg.&#xD;
&#xD;
          3. At least one measurable lesion according to the RECIST 1.1 and RANO evaluation&#xD;
             criteria.&#xD;
&#xD;
          4. ECOG performance status score is 0 or 1.&#xD;
&#xD;
          5. Blood chemistry test results, meet the following results:&#xD;
&#xD;
               1. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 ×&#xD;
                  normal upper limit (ULN)&#xD;
&#xD;
               2. Total bilirubin ≤ 1.5 × ULN&#xD;
&#xD;
               3. Serum albumin&gt; 29 g / L&#xD;
&#xD;
               4. Creatinine ≤ 1.5 × ULN or 24-hour serum creatinine clearance ≥ 50 mL / min&#xD;
&#xD;
               5. Lipase and amylase ≤ 2 × ULN.&#xD;
&#xD;
          6. Adequate bone marrow function and meets the following results:&#xD;
&#xD;
               1. Absolute neutrophil count (ANC) ≥ 1.5 × 109 / L&#xD;
&#xD;
               2. Platelets ≥ 75 × 10^9 / L&#xD;
&#xD;
               3. Hemoglobin ≥ 90 g / L.&#xD;
&#xD;
          7. Except for hearing loss and hair loss, all toxicity caused by previous anti-tumor&#xD;
             therapy must have returned to ≤ Grade 1 (according to NCI-CTCAE version 5.0).&#xD;
&#xD;
          8. Life expectancy is longer than 3 months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Have a history of hepatic encephalopathy.&#xD;
&#xD;
          2. Have a thyroid disorder with a clinically significant thyroid dysfunction judged by&#xD;
             the investigator (not applicable for thyroid cancer in dose expansion phase).&#xD;
&#xD;
          3. Active or history of upper gastrointestinal bleeding, ulcers, or esophageal varices&#xD;
             with bleeding within 6 months.&#xD;
&#xD;
          4. Have a history of HIV infection and/or acquired immunodeficiency syndrome&#xD;
&#xD;
          5. Major surgery has been performed within 4 weeks before the first dose, or is expected&#xD;
             during the study period.&#xD;
&#xD;
          6. Have a history of organ transplantation (eg., liver transplantation).&#xD;
&#xD;
          7. Poorly-controlled pleural or pericardial effusion during the screening period.&#xD;
&#xD;
          8. Other primary malignancies occurred within 5 years before the first administration of&#xD;
             the study drug with the exception of locally curable malignancies&#xD;
&#xD;
          9. Suffering from active or previously recurring autoimmune diseases or under such a&#xD;
             risk.&#xD;
&#xD;
         10. Systemically immunosuppressive drugs are currently used within 14 days of the first&#xD;
             dose.&#xD;
&#xD;
         11. The investigator considers that the complications or other situations of the subject&#xD;
             may affect compliance with the protocol, or are not suitable for participation in this&#xD;
             study.&#xD;
&#xD;
         12. Subjects with diabetes or glycated hemoglobin (HbA1c)&gt; 7%.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Li Zheng</last_name>
    <role>Principal Investigator</role>
    <affiliation>West China Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Li Zheng</last_name>
    <phone>+86 028-85423655</phone>
    <email>lzheng2005618@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chongqing Cancer Hospital</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Iris Li</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>West China of Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li Zheng</last_name>
      <phone>+86 028-85423655</phone>
      <email>lzheng2005618@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>March 21, 2020</study_first_submitted>
  <study_first_submitted_qc>April 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 7, 2020</study_first_posted>
  <last_update_submitted>May 13, 2021</last_update_submitted>
  <last_update_submitted_qc>May 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sichuan University</investigator_affiliation>
    <investigator_full_name>Li Zheng</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

